|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US20040223966A1
(en)
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
|
JP2008507288A
(ja)
*
|
2004-07-23 |
2008-03-13 |
アクセルロン ファーマ インコーポレーテッド |
ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
|
|
US20060074225A1
(en)
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
|
ES2649983T3
(es)
|
2005-11-23 |
2018-01-16 |
Acceleron Pharma, Inc. |
Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
|
|
US8101564B2
(en)
|
2006-05-03 |
2012-01-24 |
Trustees Of The University Of Pennsylvania |
Methods for regulating osteoclast differentiation and bone resorption using LRRc17
|
|
CN104524548A
(zh)
|
2006-12-18 |
2015-04-22 |
阿塞勒隆制药公司 |
活化素-actrii拮抗剂及在提高红细胞水平中的用途
|
|
US20100028332A1
(en)
|
2006-12-18 |
2010-02-04 |
Acceleron Pharma Inc. |
Antagonists of actriib and uses for increasing red blood cell levels
|
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
MX2009008222A
(es)
|
2007-02-01 |
2009-10-12 |
Acceleron Pharma Inc |
Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
|
|
TW201803890A
(zh)
|
2007-02-02 |
2018-02-01 |
艾瑟勒朗法瑪公司 |
衍生自ＡｃｔＲＩＩＢ的變體與其用途
|
|
EA018221B1
(ru)
|
2007-02-09 |
2013-06-28 |
Акселерон Фарма Инк. |
АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
|
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
|
US7947646B2
(en)
|
2007-03-06 |
2011-05-24 |
Amgen Inc. |
Variant activin receptor polypeptides
|
|
WO2009015345A1
(en)
|
2007-07-25 |
2009-01-29 |
Amgen Inc. |
Pharmaceutical compositions comprising fc fusion proteins
|
|
CN101861161B
(zh)
|
2007-09-18 |
2017-04-19 |
阿塞勒隆制药公司 |
活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
|
|
JP6157046B2
(ja)
|
2008-01-07 |
2017-07-05 |
アムジェン インコーポレイテッド |
静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
|
|
EP2242506A4
(en)
|
2008-01-07 |
2011-12-28 |
Janssen Biotech Inc |
METHOD FOR THE TREATMENT OF ERYTHROPOIETIN HYPORESPONSE ANIMALS
|
|
WO2009111793A2
(en)
|
2008-03-07 |
2009-09-11 |
Myoscience, Inc. |
Subdermal tissue remodeling using myostatin, methods and related systems
|
|
DK2318028T3
(da)
|
2008-06-26 |
2020-05-04 |
Acceleron Pharma Inc |
Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer
|
|
CN102131822A
(zh)
|
2008-06-26 |
2011-07-20 |
阿塞勒隆制药公司 |
进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法
|
|
TW201803586A
(zh)
|
2008-08-14 |
2018-02-01 |
艾瑟勒朗法瑪公司 |
使用ｇｄｆ阱以增加紅血球水平
|
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
|
JP5611222B2
(ja)
|
2008-11-26 |
2014-10-22 |
アムジエン・インコーポレーテツド |
アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用
|
|
AU2010204985A1
(en)
|
2009-01-13 |
2011-08-04 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin
|
|
KR20120049214A
(ko)
|
2009-06-08 |
2012-05-16 |
악셀레론 파마 인코포레이티드 |
발열성 지방세포를 증가시키는 방법
|
|
KR20180026795A
(ko)
|
2009-06-12 |
2018-03-13 |
악셀레론 파마 인코포레이티드 |
절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
|
|
AU2010282361B2
(en)
|
2009-08-13 |
2015-03-19 |
Acceleron Pharma Inc. |
Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
|
|
EP3202459B1
(en)
|
2009-09-09 |
2021-04-14 |
Acceleron Pharma Inc. |
Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content
|
|
AU2010315245B2
(en)
|
2009-11-03 |
2016-11-03 |
Acceleron Pharma Inc. |
Methods for treating fatty liver disease
|
|
EP3332796A1
(en)
|
2009-11-17 |
2018-06-13 |
Acceleron Pharma Inc. |
Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
|
|
MX340971B
(es)
|
2009-11-23 |
2016-08-02 |
Amgen Inc * |
Fragmento cristalizable (fc) de anticuerpo monomerico.
|
|
WO2012027065A2
(en)
|
2010-08-27 |
2012-03-01 |
Celgene Corporation |
Combination therapy for treatment of disease
|
|
AU2011326586A1
(en)
|
2010-11-08 |
2013-05-30 |
Acceleron Pharma, Inc. |
ActRIIA binding agents and uses thereof
|
|
US8501768B2
(en)
|
2011-05-17 |
2013-08-06 |
Hoffmann-La Roche Inc. |
Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
|
|
KR20140084211A
(ko)
|
2011-10-17 |
2014-07-04 |
악셀레론 파마 인코포레이티드 |
효과가 없는 적혈구생성 치료를 위한 방법 및 조성물
|
|
DK2780368T3
(en)
|
2011-11-14 |
2018-02-05 |
Regeneron Pharma |
COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
|
|
GR1007832B
(el)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
|
HK1203384A1
(en)
|
2011-12-19 |
2015-12-11 |
Amgen Inc. |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
|
KR101995751B1
(ko)
|
2012-01-05 |
2019-07-03 |
주식회사 와이바이오로직스 |
Ｄｌｋ１ 세포 외 수용성 도메인을 유효성분으로 포함하는 미오스타틴 저해제
|
|
EP2844271B1
(en)
|
2012-05-17 |
2018-02-28 |
Paranta Biosciences Limited |
Use of follistatin or of an activin inhibitor for preventing or treating tissue graft dysfunction
|
|
NZ703724A
(en)
|
2012-06-11 |
2017-06-30 |
Amgen Inc |
Dual receptor antagonistic antigen-binding proteins and uses thereof
|
|
HK1214504A1
(zh)
|
2012-10-24 |
2016-07-29 |
细胞基因公司 |
用於治療貧血的方法
|
|
WO2014138485A1
(en)
|
2013-03-08 |
2014-09-12 |
Irm Llc |
Ex vivo production of platelets from hematopoietic stem cells and the product thereof
|
|
US20160038588A1
(en)
|
2013-03-15 |
2016-02-11 |
Amgen Inc. |
Myostatin Antagonism in Human Subjects
|
|
RS61778B1
(sr)
|
2013-05-06 |
2021-06-30 |
Scholar Rock Inc |
Kompozicije i postupci za modulaciju faktora rasta
|
|
TW201920262A
(zh)
*
|
2013-07-30 |
2019-06-01 |
美商再生元醫藥公司 |
抗活化素ａ之抗體及其用途
|
|
US20160333418A1
(en)
|
2014-01-14 |
2016-11-17 |
Santa Maria Biotherapeutics, Inc. |
Activin Inhibitor Response Prediction and Uses for Treatment
|
|
JP2017509647A
(ja)
|
2014-03-21 |
2017-04-06 |
アクセルロン ファーマ， インコーポレイテッド |
アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
|
|
EP3808778A1
(en)
|
2014-04-18 |
2021-04-21 |
Acceleron Pharma Inc. |
Methods for increasing red blood cell levels and treating sickle-cell disease
|
|
CN114699529A
(zh)
|
2014-06-13 |
2022-07-05 |
阿塞勒隆制药公司 |
用于治疗溃疡的方法和组合物
|
|
PE20170471A1
(es)
|
2014-06-13 |
2017-05-14 |
Santa Maria Biotherapeutics Inc |
Polipeptidos receptores formulados y metodos relacionados
|
|
MA41052A
(fr)
|
2014-10-09 |
2017-08-15 |
Celgene Corp |
Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
|
|
GB201421379D0
(en)
|
2014-12-02 |
2015-01-14 |
Isis Innovation Ltd And Medical Res Council |
Molecule
|
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
|
JP2018501307A
(ja)
|
2014-12-03 |
2018-01-18 |
セルジーン コーポレイション |
アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
|
|
US10358476B2
(en)
*
|
2015-04-06 |
2019-07-23 |
Acceleron Pharma Inc. |
Single arm type I and type II receptor fusion proteins and uses thereof
|
|
MA41920B1
(fr)
|
2015-04-06 |
2021-05-31 |
Acceleron Pharma Inc |
Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
|
|
CA2983440C
(en)
|
2015-04-22 |
2024-03-12 |
Alivegen Usa Inc. |
Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
|
|
US20180125928A1
(en)
|
2015-05-13 |
2018-05-10 |
Celgene Corporation |
Treatment of beta-thalassemia using actrii ligand traps
|
|
CN108350057A
(zh)
|
2015-05-20 |
2018-07-31 |
细胞基因公司 |
使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法
|
|
WO2017079591A2
(en)
|
2015-11-04 |
2017-05-11 |
Acceleron Pharma Inc. |
Methods for increasing red blood cell levels and treating ineffective erythropoiesis
|
|
EP3380121B1
(en)
|
2015-11-23 |
2023-12-20 |
Acceleron Pharma Inc. |
Actrii antagonist for use in treating eye disorders
|
|
US20170240639A1
(en)
|
2016-02-22 |
2017-08-24 |
Acceleron Pharma Inc. |
Actrii antagonists for use in increasing immune activity
|
|
DK3496739T3
(da)
|
2016-07-15 |
2021-05-10 |
Acceleron Pharma Inc |
Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
|
|
MA45811A
(fr)
|
2016-07-27 |
2019-06-05 |
Acceleron Pharma Inc |
Méthodes et compositions de traitement de maladie.
|
|
CN110036025B
(zh)
|
2016-10-05 |
2024-03-22 |
阿塞勒隆制药公司 |
变体ActRIIB蛋白及其用途
|
|
CA3039074A1
(en)
|
2016-10-05 |
2018-04-12 |
Acceleron Pharma Inc. |
Compositions and method for treating kidney disease
|
|
JOP20190085A1
(ar)
|
2016-10-20 |
2019-04-17 |
Biogen Ma Inc |
طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
|
|
WO2018089702A1
(en)
|
2016-11-10 |
2018-05-17 |
Keros Therapeutics, Inc. |
Gdnf fusion polypeptides and methods of use thereof
|
|
NZ754161A
(en)
|
2016-11-10 |
2025-11-28 |
Keros Therapeutics Inc |
Activin receptor type iia variants and methods of use thereof
|
|
GB201620119D0
(en)
|
2016-11-29 |
2017-01-11 |
Pharmafox Therapeutics Ag |
Compounds
|
|
EP3576773B1
(en)
|
2017-02-01 |
2023-10-18 |
Acceleron Pharma Inc. |
Tgf beta and actrii antagonists for use in treating leukemia
|
|
CA3052625A1
(en)
|
2017-02-06 |
2018-08-09 |
Acceleron Pharma Inc. |
Compositions and methods for treating heart failure
|
|
PL3638243T3
(pl)
|
2017-06-14 |
2025-02-10 |
Celgene Corporation |
Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistości
|
|
CA3082146A1
(en)
*
|
2017-11-09 |
2019-05-16 |
Keros Therapeutics, Inc. |
Activin receptor type iia variants and methods of use thereof
|
|
IL320014A
(en)
|
2018-01-12 |
2025-06-01 |
Keros Therapeutics Inc |
Activin receptor type iib variants and methods of use thereof
|
|
KR20250133994A
(ko)
|
2018-05-09 |
2025-09-09 |
케로스 테라퓨틱스, 인크. |
액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
|
|
US20220372135A1
(en)
|
2019-09-27 |
2022-11-24 |
Disc Medicine, Inc. |
Methods for treating myelofibrosis and related conditions
|
|
WO2021189006A1
(en)
|
2020-03-20 |
2021-09-23 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type iia variants
|
|
WO2021189010A1
(en)
|
2020-03-20 |
2021-09-23 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type iib variants
|
|
WO2021189019A1
(en)
|
2020-03-20 |
2021-09-23 |
Keros Therapeutics, Inc. |
Activin receptor type ii chimeras and methods of use thereof
|
|
CA3193654A1
(en)
|
2020-10-02 |
2022-04-07 |
Jasbir S. Seehra |
Methods of using activin receptor type ii variants
|
|
WO2022235620A1
(en)
|
2021-05-04 |
2022-11-10 |
Keros Therapeutics, Inc. |
Activin receptor type ii chimeras and methods of use thereof
|
|
WO2022271716A2
(en)
|
2021-06-21 |
2022-12-29 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii signaling inhibitors
|
|
KR20240051971A
(ko)
|
2021-08-19 |
2024-04-22 |
케로스 테라퓨틱스, 인크. |
액티빈 수용체 ii형 신호전달 억제제를 이용한 방법
|
|
WO2024054985A2
(en)
|
2022-09-09 |
2024-03-14 |
Keros Therapeutics, Inc. |
Methods of administering an activin type iib variant
|
|
WO2024102906A2
(en)
|
2022-11-10 |
2024-05-16 |
Keros Therapeutics, Inc. |
Activin receptor type ii chimeras and methods of use thereof
|
|
WO2024238950A1
(en)
|
2023-05-18 |
2024-11-21 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii variants
|
|
WO2024238920A1
(en)
|
2023-05-18 |
2024-11-21 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii variants
|